Q-omics provides the consensus-scored ZBED6CL profile across patient tissues and cancer cell-line models. ZBED6CL expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZBED6CL is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ZBED6CL RNA expression shows 17,471 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where ZBED6CL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBED6CL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBED6CL survival associations across molecular data types. ZBED6CL RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBED6CL RNA expression–survival associations across cancer types. High ZBED6CL expression shows unfavorable associations in LIHC, KIRC and COAD, but favorable associations in ACC, BRCA and READ. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for ZBED6CL RNA expression.
This table summarizes ZBED6CL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZBED6CL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBED6CL shows higher tumor expression in KIRC, HNSC, LIHC, KIRP, BLCA and COAD. The KIRC box plot shows higher ZBED6CL RNA expression in tumor versus normal tissue (log2 FC = +1.109, t-test p < 0.001).
This table shows molecular features associated with ZBED6CL in patient tissues and cancer cell lines. In patient samples, ZBED6CL shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBED6CL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
